The average one-year price target for Hoth Therapeutics (NasdaqCM:HOTH) has been revised to $5.10 / share. This is an increase of 11.11% from the prior estimate of $4.59 dated January 11, 2026.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $5.05 to a high of $5.25 / share. The average price target represents an increase of 508.16% from the latest reported closing price of $0.84 / share.
What is the Fund Sentiment?
There are 26 funds or institutions reporting positions in Hoth Therapeutics. This is an increase of 7 owner(s) or 36.84% in the last quarter. Average portfolio weight of all funds dedicated to HOTH is 0.00%, an increase of 2,401.84%. Total shares owned by institutions increased in the last three months by 256.70% to 1,269K shares.
What are Other Shareholders Doing?
Renaissance Technologies holds 244K shares representing 1.57% ownership of the company.
Geode Capital Management holds 154K shares representing 0.99% ownership of the company. In its prior filing, the firm reported owning 123K shares , representing an increase of 20.16%. The firm decreased its portfolio allocation in HOTH by 16.15% over the last quarter.
Citadel Advisors holds 143K shares representing 0.92% ownership of the company. In its prior filing, the firm reported owning 0K shares , representing an increase of 100.00%.
Virtu Financial holds 113K shares representing 0.73% ownership of the company. In its prior filing, the firm reported owning 0K shares , representing an increase of 100.00%.
Hrt Financial holds 85K shares representing 0.55% ownership of the company. In its prior filing, the firm reported owning 0K shares , representing an increase of 100.00%.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
